Human VEGF QuantiGlo ELISA Kit

  (19 citations)     
Datasheet / CoA / SDS
Product Details
Citations (19)
FAQs
Supplemental Products
Reviews
  • Assay Length
    5.5 hours
  • Sample Type & Volume Required Per Well
    Cell Culture Supernates (50 uL), Serum (50 uL), EDTA Plasma (50 uL), Heparin Plasma (50 uL), Saliva (50 uL), Urine (50 uL)
  • Sensitivity
    5.99 pg/mL
  • Assay Range
    6.4 - 20,000 pg/mL (Cell Culture Supernates, Serum, EDTA Plasma, Heparin Plasma, Saliva, Urine)
  • Specificity
    Natural and recombinant human VEGF. This assay also recognizes recombinant human VEGF165b.
  • Cross-reactivity
    Cross-reactivity observed with 1 or more available related molecules.< 50% cross-species reactivity observed with species tested.
  • Interference
    Interference observed with 1 or more available related molecules.
Control Available
QC198 , QuantiGlo Immunoassay Control Set 732 for Human VEGF - Please Inquire
Product Summary
The QuantiGlo Human VEGF Chemiluminescent Immunoassay is a 5.5 hour solid phase ELISA designed to measure VEGF165 levels in cell culture supernates, serum, plasma, saliva, and urine. It contains Sf 21-expressed recombinant human VEGF165 and antibodies raised against the recombinant protein. Results obtained for naturally occurring human VEGF and recombinant human VEGF121 showed linear curves that were parallel to the standard curves obtained using the QuantiGlo kit standards. These results indicate that this kit can be used to determine relative mass values for natural human VEGF.

Precision
Intra-Assay Precision (Precision within an assay) Four samples of known concentration were tested on one plate to assess intra-assay precision
Inter-Assay Precision (Precision between assays) Four samples of known concentration were tested in separate assays to assess inter-assay precision
Cell Culture Supernates, Serum, EDTA Plasma, Heparin Plasma, Saliva
Intra-Assay Precision Inter-Assay Precision
Sample 1 2 3 4 1 2 3 4
n 20 20 20 20 20 20 20 20
Mean 22.2 392 1857 13972 22.7 389 1843 13411
Standard Deviation 1.76 12.9 52.3 557 2 27.6 131 562
CV% 7.9 3.3 2.8 4 8.8 7.1 7.1 4.2

Urine
Intra-Assay Precision Inter-Assay Precision
Sample 1 2 3 4 1 2 3 4
n 20 20 20 20 20 20 20 20
Mean 24.4 417 1999 14245 22.9 383 1823 12825
Standard Deviation 1.24 16 44.9 608 2.36 28.9 141 536
CV% 5.1 3.8 2.2 4.3 10.3 7.5 7.7 4.2

Recovery

The recovery of VEGF spiked to three different levels throughout the range of the assay in various matrices was evaluated.

Sample Type Average % Recovery Range %
Cell Culture Media (n=4) 103 95-113
EDTA Plasma (n=4) 104 98-110
Heparin Plasma (n=4) 104 96-111
Serum (n=4) 102 90-112
Urine (n=4) 99 90-106
Linearity
To assess the linearity of the assay, samples containing or spiked with high concentrations of VEGF in various matrices were diluted with Calibrator Diluent to produce samples with values within the dynamic range of the assay.
 VEGF [HRP]
Product Datasheets

Certificate of Analysis Lookup

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Certificate of Analysis Lookup

Certificate of Analysis Request Form

To download a Certificate of Analysis, please enter the catalog and lot numbers in the search box below.

Note: Certificate of Analysis not available for kit components.

Preparation and Storage
  • Storage
    Store the unopened product at 2 - 8 °C. Do not use past expiration date.
Background: VEGF
VEGF (Vascular endothelial growth factor) is a potent mediator of both angiogenesis and vasculogenesis in the fetus and adult. It is required for regulating the proliferation, migration, and survival of embryonic endothelial cells and during wound healing and the female reproductive cycle in adults. Pathologically, it is involved in tumor development and tumor vascular leakage. VEGF binds to VEGF R1/Flt-1, VEGF R2/Flk-1/KDR, and Neuropilin-1. Multiple forms of VEGF are generated by alternative splicing and proteolysis.
  • Long Name:
    Vascular Endothelial Growth Factor
  • Entrez Gene IDs:
    7422 (Human); 22339 (Mouse); 83785 (Rat); 281572 (Bovine); 403802 (Canine); 493845 (Feline); 30682 (Zebrafish)
  • Alternate Names:
    MVCD1; VAS; vascular endothelial growth factor A; Vascular permeability factor; Vasculotropin; VEGF; VEGFA; VEGF-A; VEGFMGC70609; VPF; VPFvascular endothelial growth factor
Related Research Areas
Citations:

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

19 Citations: Showing 1 - 10
Filter your results:

Species
Sample Type
  1. Downregulation of tumor suppressive microRNAs in vivo in dense breast tissue of postmenopausal women
    Authors: A Abrahamsso, A Capodanno, A Rzepecka, C Dabrosin
    Oncotarget, 2017;8(54):92134-92142.
    Species: Human
    Sample Type: Cell Culture Supernates
  2. Hypoxic Preconditioning Increases Survival and Pro-Angiogenic Capacity of Human Cord Blood Mesenchymal Stromal Cells In Vitro.
    Authors: Bader A, Klose K, Bieback K, Korinth D, Schneider M, Seifert M, Choi Y, Kurtz A, Falk V, Stamm C
    PLoS ONE, 2015;10(9):e0138477.
    Species: Human
    Sample Type: Cell Culture Supernates
  3. Aging impairs VEGF-mediated, androgen-dependent regulation of angiogenesis.
    Authors: Lecce, Laura, Lam, Yuen Tin, Lindsay, Laura A, Yuen, Sui Chin, Simpson, Philippa, Handelsman, David J, Ng, Martin K
    Mol Endocrinol, 2014;28(9):1487-501.
    Species: Human
    Sample Type: Cell Culture Supernates
  4. Inflammation induced by MMP-9 enhances tumor regression of experimental breast cancer.
    Authors: Leifler K, Svensson S, Abrahamsson A, Bendrik C, Robertson J, Gauldie J, Olsson A, Dabrosin C
    J Immunol, 2013;190(8):4420-30.
    Species: Mouse
    Sample Type: Tissue Homogenates
  5. Vascular endothelial growth factor-A (VEGF-A) and chemokine ligand-2 (CCL2) in Amyotrophic Lateral Sclerosis (ALS) patients.
    Authors: Gupta PK, Prabhakar S
    J Neuroinflammation, 2011;8(1):47.
    Species: Human
    Sample Type: CSF
  6. Overexpression of tumor vascular endothelial growth factor A may portend an increased likelihood of progression in a phase II trial of bevacizumab and erlotinib in resistant ovarian cancer.
    Authors: Chambers SK, Clouser MC, Baker AF, Roe DJ, Cui H, Brewer MA, Hatch KD, Gordon MS, Janicek MF, Isaacs JD, Gordon AN, Nagle RB, Wright HM, Cohen JL, Alberts DS
    Clin. Cancer Res., 2010;16(21):5320-8.
    Species: Human
    Sample Type: Urine
  7. Clinical correlations and prognostic relevance of HGF, VEGF AND FGF expression in Brazilian patients with non-Hodgkin lymphoma.
    Authors: Etto L, Lacerda E, Baiocchi O, Silva V, Dalboni M, Alves A, Silva M, Vettore A, Colleoni G
    Leuk. Lymphoma, 2008;49(2):257-64.
    Species: Human
    Sample Type: Serum
  8. Gene transfer of matrix metalloproteinase-9 induces tumor regression of breast cancer in vivo.
    Authors: Bendrik C, Robertson J, Gauldie J, Dabrosin C
    Cancer Res., 2008;68(9):3405-12.
    Species: Human
    Sample Type: Tissue Homogenates
  9. Regulation of angiogenic factors by HDM2 in renal cell carcinoma.
    Authors: Carroll VA, Ashcroft M
    Cancer Res., 2008;68(2):545-52.
    Species: Human
    Sample Type: Cell Culture Supernates
  10. Dietary lariciresinol attenuates mammary tumor growth and reduces blood vessel density in human MCF-7 breast cancer xenografts and carcinogen-induced mammary tumors in rats.
    Authors: Saarinen NM, Warri A, Dings RP, Airio M, Smeds AI, Mäkelä S
    Int. J. Cancer, 2008;123(5):1196-204.
    Species: Human
    Sample Type: Cell Culture Supernates
  11. Very low density lipoprotein receptor, a negative regulator of the wnt signaling pathway and choroidal neovascularization.
    Authors: Chen Y, Hu Y, Lu K, Flannery JG, Ma JX
    J. Biol. Chem., 2007;282(47):34420-8.
    Species: Human
    Sample Type: Cell Culture Supernates
  12. Selective inhibition of MEK1/2 reveals a differential requirement for ERK1/2 signalling in the regulation of HIF-1 in response to hypoxia and IGF-1.
    Authors: Sutton KM, Hayat S, Chau NM, Cook S, Pouyssegur J, Ahmed A, Perusinghe N, Le Floch R, Yang J, Ashcroft M
    Oncogene, 2007;26(27):3920-9.
    Species: Human
    Sample Type: Cell Culture Supernates
  13. Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer.
    Authors: Kut C, Mac Gabhann F, Popel AS
    Br. J. Cancer, 2007;97(7):978-85.
    Species: Human
    Sample Type: Serum
  14. Sphingosine kinase 1 is up-regulated during hypoxia in U87MG glioma cells. Role of hypoxia-inducible factors 1 and 2.
    Authors: Anelli V, Gault CR, Cheng AB, Obeid LM
    J. Biol. Chem., 2007;283(6):3365-75.
    Species: Human
    Sample Type: Cell Culture Supernates
  15. Increased vascular endothelial growth factor and receptors: relationship to angiogenesis in asthma.
    Authors: Feltis BN, Wignarajah D, Zheng L, Ward C, Reid D, Harding R, Walters EH
    Am. J. Respir. Crit. Care Med., 2006;173(11):1201-7.
    Species: Human
    Sample Type: BALF
  16. Role of hypoxia-inducible factor (HIF)-1alpha versus HIF-2alpha in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von Hippel-Lindau function: implications for targeting the HIF pathway.
    Authors: Carroll VA, Ashcroft M
    Cancer Res., 2006;66(12):6264-70.
    Species: Human
    Sample Type: Cell Culture Supernates
  17. Protease-activated receptor-2 regulates vascular endothelial growth factor expression in MDA-MB-231 cells via MAPK pathways.
    Authors: Mueller BM
    Biochem. Biophys. Res. Commun., 2006;344(4):1263-70.
    Species: Human
    Sample Type: Cell Culture Supernates
  18. Dynamic contrast-enhanced MRI to quantify VEGF-enhanced tissue-engineered bladder graft neovascularization: pilot study.
    Authors: Cartwright L, Farhat WA, Sherman C, Chen J, Babyn P, Yeger H, Cheng HL
    J Biomed Mater Res A, 2006;77(2):390-5.
    Species: Rabbit
    Sample Type: Cell Culture Supernates
  19. Evaluating hypoxia-inducible factor-1alpha as a cancer therapeutic target via inducible RNA interference in vivo.
    Authors: Li L, Lin X, Staver M, Shoemaker A, Semizarov D, Fesik SW, Shen Y
    Cancer Res., 2005;65(16):7249-58.
    Species: Human
    Sample Type: Tissue Homogenates
Expand to show all Citations

FAQs

No product specific FAQs exist for this product, however you may

View all ELISA FAQs
ELISA Controls
Description Application Cat# Citations Images  

QuantiGlo Immunoassay Control Set 732 for Human VEGF

Ctrl QC198
View Sizes & Prices
Catalog# Size Price Stock Quantity
Loading Information....

Have you used Human VEGF QuantiGlo ELISA Kit?

Submit a review and receive a $25US/€18/£15/$25CAN amazon gift card if you include an image - $10US/€7/£6/$10CAN Amazon card for reviews without an image. Limited to verified customers in USA, Canada and Europe.

Order Details

Contact Us to Order
reload

Feedback

Customer Information
R&D Systems Guarantee